Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic

Thrifty Thinkers
9 followers
1 Video View·Oct 31, 2024
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported third-quarter adjusted profit and revenue that missed expectations, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, why the company is slashing its full-year adjusted profit guidance, and more.
Joining us now to break down the report, Eli Lilly, CEO David Ricks, and we know how we've
seen this movie before, I think, David, things do get very excitable about great products.
I think your stock's up 50 percent.
It's almost almost got to a trillion dollars, which is would have been the first drug company
I think ever to get there.
So there's been great things happening.
This is this three step forward.
One step back.
How do you view it?
Well, we we had a really strong quarter, so I know there's a difference in what the street
expected, but to be honest, we're pretty pleased with how things turned out up.
Forty two percent year over year on the right.
Compare. I think that's a pretty small group of companies our size growing at that rate.
And sequentially, if you look at in-market prescription growth, it's actually accelerating in the U.S.
So while reported sales are like compared to the street estimates, we're on track with what we want.
We are taking a little bit off the top of our guide because during the quarter, I think we we changed an assumption.
We changed the assumption that we should start promoting and launching sooner in the U.S.
and in other markets.
And we basically push that some of that out into Q4 because of customer service levels.
So we want to make sure people, when they get a prescription, can fill it.
We understand that's a frustration for our customers.
So we relax that constraint a bit.
And so there's a little lighter demand in the year and now projected.
But overall, I think we're a pretty healthy shape and underlying demand is extremely strong.
I'm trying to understand that you concede maybe demand is a little bit lighter.
And then in terms of lowering, as you said, the street was expecting this, but they were the street was basing their expectations on your guidance.
And your guidance on the top end for revenue did come down a little.
Is that 100 percent of that because of of the customer service concerns and pushing it into the fourth quarter or anything else to account for the the high end of the yearly guidance coming down?
Yeah, it's it's really that I mean, we moved out plans to advertise and promote Zepp bound, which we're not really doing right now.
We're just starting that now in Q4.
So here in November, mid-November on, we'll begin that in the U.S.
And then outside the U.S., we held back on launches.
So those activities which drive revenue, we we slow down a bit because we want to make sure our inventory levels at Lilly and in the channel rise.
Now, I think Angelica was speaking earlier there about the channel dynamics, which we cite in our press release.
And we did have a lot of inventory going into the quarter.
We had a lot less going out in the channel.
So I think this is not a function of supply, though.
It's a function of the, you know, these wholesalers and retailers having capacity and wanting to stock every dose, which they often don't.
So, yeah, we're just balancing all these parts.
And, you know, there is an excess supply, but we haven't been stimulating demand the way we had originally planned.
So we're we're pausing that a bit.
We did pause that, but we're restarting here.
So, look, the growth story, though, is fantastic underlying this.
And Inkerton's are which are Zepp bound and Monja are growing pretty dramatically.
We plan for that to continue.
Dave, it's nice to talk to you again, but it's interesting because last quarter you were saying that you really didn't even need to promote Zepp bound.
It was basically promoting itself because there was so much demand.
And now it sounds like you're almost saying that you need to go out there and do more promotion.
Is that right? Or you see demand softening at this point?
No, I think if we had juiced promotion in the quarter, we might have risked on some dosage forms, people having a bad experience going to the pharmacy counter and not having it available, etc.
Again, there's a you know, this supply chain is very tightly managed.
We're still in the growth.
We're investing heavily, as you know, in that we're still in the growth phase of that expanding capacity pretty dramatically.
We're on track to hit our goal of at least 50 percent year over year growth in the second half of this year versus second half of last year.
But when people go and they can't get their medicine, they're very frustrated.
They tell us that. So, you know, we didn't want to send more people to do that necessarily.
That said, underlying sequential prescription growth is up 25 percent Q3 over Q2.
So a lot more people went to get the prescription, even though we did not promote.
But we are going to start that because we do expect even greater expansion in our manufacturing capacity exiting the year and into next year.
And how much of the supply situation has to do with the fact that you want to make sure that triseptide is available so that it's off the FDA shortage list?
Obviously, that's been a big issue with you and the compounders.
So how much of that dynamic is at play here?
I mean, it's a factor of our key indicator, though, is is fill rate at the pharmacy counter for consumers.
So when that is slipping down, meaning people are unsuccessful in fulfilling a prescription the first time or the second time, that's when we that's what we pay attention to.
A byproduct of that is what the FDA decides to do.
We don't really control that.
We give them the relevant information.
How much stock is it, Lily?
Which, as I said, we have available supply on all available, all doses of Manjaro and Zepp bound.
And they make a determination whether it's in shortage or not.
We agree it's not in shortage because we have stock.
The other issue, David, are these these copycats.
I know you're going after them, suing some of them, but is that like a whack a mole game to try and come up with the biggest copycat issues on this?
What risks are there for consumers if they're going that route instead of going through a doctor?
Yeah, I mean, the primary concern there is one of safety.
A lot of these outfits are dispensing drugs without doctor supervision, certainly not an in-person visit.
They are not FDA regulated.
They claim they're regulated by state boards of pharmacies.
But, you know, I don't think they're getting inspected.
They're not approved drugs, really.
So we're we're we've created a world here where there are these knockoffs that people can access.
And our point of view is that needs to get put back in the box.
We have the FDA for a reason, which is we want to have consumers confident when they go to the get a prescription that it's the dose and the the medicine that they expect it to
have and it's safe and effective.
None of these other guys can say that.
How much of a frustration is that?
And what do you think the government should be doing?
Well, I think it's not really a business matter for us, as we just talked about.
We're sort of selling what we make and it's a tight supply chain for us.
I just worry long term if we're sort of avoiding the real issue here, which is coverage of these medications on insurance.
I think that's really what's happening is people want to buy a lower priced product, even though it's lower quality.
It's not a real medicine.
It's not an approved medicine.
That's what compounding is.
What we need to do is bring those people into the insurance system.
And, you know, if we have other diseases like diabetes or hypertension, we expect our medicine to be covered by insurance.
Why is this different? You know, that needs to change.
I think that's the primary thing I'm worried about.
